Form 4: Crinetics Pharmaceuticals Director Wendell Wierenga Reports Acquisition of Stock and Options

Director Wendell Wierenga reports acquisition of 3,400 shares of common stock and 12,500 stock options in Crinetics Pharmaceuticals.

Summary

• On June 7, 2024, Wendell Wierenga, a director of Crinetics Pharmaceuticals, acquired 3,400 shares of common stock and 12,500 stock options.
• The common stock was acquired through restricted stock units, which vest on the earlier of the first anniversary of the grant date or the next annual meeting, contingent upon continued service on the board.
• The stock options, with an exercise price of $44.71, also vest on the earlier of the first anniversary of the grant date or the next annual meeting, subject to continued board service.
• Following these transactions, Wierenga directly owns 109,246 shares of Crinetics Pharmaceuticals common stock and 12,500 stock options.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment, but rather reports factual transactions.

Positives

• The acquisition of stock and options by a director signals confidence in the company's future prospects.

Future Outlook

The vesting of the restricted stock units and stock options is contingent upon the Reporting Person's continued service on the board of directors of the Issuer.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment as it indicates confidence from a company director.

Key Dates